Abstracts tagged "Animal models"

Abstract Number: 2421 • 2017 ACR/ARHP Annual Meeting
Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Tomohiro Koga¹, Tomohito Sato¹, Masataka Umeda², Shoichi Fukui², Ayako Nishino¹, Shinya Kawashiri², Naoki Iwamoto², Kunihiro Ichinose², Mami Tamai¹, Tomoki Origuchi³, Hideki Nakamura² and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown of peripheral tolerance, which leads to aberrant Th1- or Th17-driven immune…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1337 • 2017 ACR/ARHP Annual Meeting
ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis
David Zammit¹, Sanjeeva Reddy¹, Roger Smith¹, Nitin Damle² and Sandeep Gupta¹, ¹Asana BioSciences LLC, Lawrenceville, NJ, ²Preclinical R&D, Sun Pharma Advanced Research Co. Ltd, Mumbai, India
Background/Purpose: Spleen tyrosine kinase (SYK) and Janus kinase (JAK) mediate signaling in immune cells and hematopoietic cells important for the initiation and progression of rheumatoid…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
Abstract Number: 1339 • 2017 ACR/ARHP Annual Meeting
Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis
Marta Fernandez Bustmanate¹, Jeffrey Smith², Adam Paul Croft³, Gary S. Firestein⁴, Chris Buckley⁵, Shigeki Miyamoto² and Monica Guma⁶, ¹Medicine, UCSD, San Diego, CA, ²Pharmacology, UCSD, La Jolla, CA, ³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Medicine, University of California San Diego, La Jolla, CA, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Medicine, UCSD, La Jolla, CA
Background/Purpose: Recent studies indicate that fibroblast-like synoviocyte (FLS) glucose metabolism is altered in rheumatoid arthritis (RA). Hexokinases (HKs) catalyze the first step in glucose metabolism.…
Abstract Number: 2574 • 2017 ACR/ARHP Annual Meeting
Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation
Mo Yin Mok¹, Ka Sin Law², Wing Yin Kong¹, Ge Liu¹, Wallace Lau², C Luo², FP Huang³, GC Chan⁴ and Kwok Wah Chan³, ¹Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of…
Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland
Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting
Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Adam Paul Croft¹, Joana Campos², Loriane Savary², Emma Bishop², Jason Turner¹, Guillaume Desanti², Francesca Barone³, Andrew Filer³ and Chris Buckley², ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
Abstract Number: 1578 • 2017 ACR/ARHP Annual Meeting
The Initiation, but Not the Persistence, of Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats Is Crucially Dependent on the IL-23 Axis
Melissa van Tok^1,2, Songqing Na³, Joel Taurog⁴, Dominique Baeten^2,5 and Leonie van Duivenvoorde^1,2, ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Eli Lilly and Company, Indianapolis, IN, ⁴Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A is a central driver of spondyloarthritis (SpA) pathology. IL-17A production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence from…
Abstract Number: 2927 • 2017 ACR/ARHP Annual Meeting
Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Minghua Wu¹, Gloria Salazar¹, Jun Ying¹, Julio Charles², Xiaodong Zhou³, Maureen D. Mayes² and Shervin Assassi², ¹Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, TX, ³Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Previous global gene expression studies of SSc patients revealed presence of a prominent type I interferon (IFN) signature. IRF7 is a key transcription factor…
Abstract Number: 57 • 2017 ACR/ARHP Annual Meeting
Accelerated Development of Aging-Associated and Instability-Induced Osteoarthritis in 12/15-Lipoxygenase Deficient Mice
Lauris Habouri¹, Yassine Ouhaddi¹, Gadid Guedi¹, Jean-Pierre Pelletier², Johanne Martel-Pelletier², mohamed benderdour¹ and Hassan Fahmi², ¹Medicine, CRCHUM, Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: 12/15-Lipoxygenase (12/15-LOX) catalyzes the generation of various anti-inflammatory lipid mediators, and has been implicated in several inflammatory and degenerative diseases. However, there is currently…
Abstract Number: 865 • 2017 ACR/ARHP Annual Meeting
Lasp-1 Regulates Cell-Matrix and Cell-Cell Contacts in Arthritic Mouse Models
Denise Beckmann¹, Annika Krause², Uwe Hansen¹, Hans Peter Kiener³, Thomas Kamradt⁴, Catherine S. Chew⁵, Thomas Pap² and Adelheid Korb-Pap¹, ¹Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Institute for Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Institute of Immunology, University Hospital Jena, Jena, Germany, ⁵Institute of Molecular Medicine and Genetics, Medical College of GA, GA, GA
Background/Purpose: In rheumatoid arthritis (RA) the attachment of synovial fibroblasts (SF) to articular cartilage is an important prerequisite in the process of cartilage degradation. The…
Abstract Number: 1708 • 2017 ACR/ARHP Annual Meeting
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Janine Schniering¹, Martina Benesova^2,3, Matthias Brunner⁴, Carol A. Feghali-Bostwick⁵, Roger Schibli^2,3, Oliver Distler⁶, Cristina Müller^2,3 and Britta Maurer⁶, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Chemistry and Applied Biosciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, Zurich, Switzerland, ³Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland, Villigen PSI, Switzerland, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a life-threatening complication in SSc. In recent years, distinct genomic and molecular subtypes in SSc-ILD were identified and molecular…
Abstract Number: 2928 • 2017 ACR/ARHP Annual Meeting
STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis
Debomita Chakraborty¹, Barbora Šumová², Tatjana Mallano³, Chih-Wei Chen³, Alfiya Distler³, Christina Bergmann³, Andreas Ramming⁴, Oliver Distler⁵, Georg Schett³, Ladislav Senolt⁶ and Jörg Distler³, ¹Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ²Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates key cellular processes such as proliferation, apoptosis, invasion, angiogenesis, metastasis…

« Previous Page
1
…
5
6
7
8
9
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].